Koers Enzolytics Inc. Other OTC
Aandelen
ENZC
US2941121079
Biotechnologie & Medisch Onderzoek
Omzet 2009 | 0,01 0,01 | Omzet 2010 | 0,04 0,03 | Marktkapitalisatie | 7,45 mln. 6,92 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2009 | - 0 | Nettowinst (verlies) 2010 | -7 mln. -6,5 mln. | EV/omzet 2009 | 325.315.067 x |
Nettoschuld 2009 | 924K 858K | Nettoschuld 2010 | 328K 304K | EV/omzet 2010 | 210.445.953 x |
K/w-verhouding 2009 * |
-
| K/w-verhouding 2010 |
-0,29
x | Werknemers | - |
Dividendrendement 2009 * |
-
| Dividendrendement 2010 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Harry Zhabilov
CHM | Chairman | 57 | 16-06-17 |
Joseph Cotropia
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gaurav Chandra
BRD | Director/Board Member | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Harry Zhabilov
CHM | Chairman | 57 | 16-06-17 |
Joseph Cotropia
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gaurav Chandra
BRD | Director/Board Member | - | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+3,91% | 109 mld. | |
+10,87% | 105 mld. | |
+1,28% | 22,25 mld. | |
-13,14% | 22,09 mld. | |
-7,05% | 18,68 mld. | |
-38,36% | 17,58 mld. | |
-10,66% | 16,85 mld. | |
+3,75% | 13,76 mld. | |
+36,70% | 12,46 mld. |